ClinicalTrials.gg
CompletedNCT00941681Updated Feb 12, 2013Results posted

Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart Failure

A Phase 2 interventional study of CK-1827452 and CK-1827452 in Heart Failure, sponsored by Cytokinetics. Completed at 3 sites in Georgia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-02-12.

Sponsored by Cytokinetics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing omecamtiv mecarbil in Heart Failure — 1 open to participants now, 1 under way, 1 of them phase 3. omecamtiv mecarbil · Heart Failure.

Enrollment
9th of 14
35 · median 48
Started
2009
the only one that year
Phase 2
7 of 14
none open now
Registered
4th of 14
by date
Lead sponsor
14 of 14
Cytokinetics

Among the 14 studies testing omecamtiv mecarbil in Heart Failure, this one is the 9th largest by enrollment, is the only one that started in 2009, is one of 7 in phase 2, and was the 4th registered.

Heart Failure

6,337 studies on the registry are indexed under Heart Failure; 1,396 are open to participants now.

Browse Heart Failure studies →

Open to participants now

1 of the 14 studies testing omecamtiv mecarbil in Heart Failure is open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About omecamtiv mecarbil

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing omecamtiv mecarbil in Heart Failure, or all of them as a file.
02

Study summary

This study is designed to understand the pharmacokinetics of different oral formulations of CK-1827452 being considered for future studies in patients with heart failure. This study will compare the pharmacokinetics and safety and tolerability of both modified-release (MR) and immediate-release (IR) oral formulations of CK-1827452.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • omecamtiv mecarbil
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient has signed an Form/Patient Information Sheet for this study approved by the governing Institutional Review Board (IRB) or Independent Ethics Committee (IEC)
  2. The patient is at least 18 years old at the time of consent
  3. (LVEF) ≤ 35% as determined by the Investigator within 3 weeks prior to enrollment
  4. Treated for at least 4 weeks with a beta blocker and an ACE inhibitor (and/or an ARB) unless not tolerated. If prescribed, diuretics must have been administered according to a consistent regimen for at least 4 weeks.
  5. Diagnosed with heart failure for ≥ 3 months prior to enrollment
  6. Patient is considered to be an appropriate candidate for study enrollment as determined by the patient's clinical laboratory findings, vital signs and ECGs within normal range, or if outside of the normal range not deemed in the opinion of the Investigator
  7. For female patients only: The patient is (≥ 1 year) or sterilized, or if she is of , she is not breastfeeding, her pregnancy test is negative, she has no intention to become pregnant during the course of the study, and she is using drugs or devices. For male patients only: Male patients agree for the duration of the study and 10 weeks after the end of the study to use a condom during sexual intercourse with female partners who are of and to have female partners use an additional effective means of contraception (eg, diaphragm plus spermicide, or oral contraceptives) or the male subject must agree to abstain from sexual intercourse for 10 weeks after the end of the study.

Exclusion criteria

Exclusion Criteria:

  1. Patient has been hospitalised for heart failure, acute coronary syndrome, myocardial infarction, coronary revascularisation, or stroke, cardiac arrhythmia, or major surgery within 6 weeks prior to enrollment
  2. Poorly controlled hypertension defined as blood pressure > 150/95 mmHg, documented on at least 2 separate occasions prior to enrollment
  3. The patient has a supine heart rate ≥ 100 beats per minute after 10 minutes of rest
  4. Patient has a troponin I at screening that is above the
  5. The patient has severe aortic or mitral stenosis
  6. The patient has active myocarditis; restrictive, constrictive, or hypertrophic obstructive cardiomyopathy; clinically significant congenital heart disease; history of major organ transplantation
  7. The patient has Canadian Cardiovascular Society Class IV angina
  8. Patient is on chronic anti-arrhythmic therapy, with the exception of amiodarone
  9. Patient has impaired renal function defined as an estimated ≤ 30 ml/min/1.73 m2 calculated by the Modification of Diet in Renal Disease (MDRD) equation
  10. Patient is currently taking, or has taken within 14 days prior to enrollment, a potent inhibitor (medication or food). Patient is currently taking, or has taken within 28 days prior to enrollment, a potent CYP3A4 inducer (medication or food).
  11. The patient has hepatic impairment defined as a total > 3 mg/dL, or an or AST > 2 times the upper limit of normal
  12. Concomitant non-cardiovascular disease that is expected to reduce to less than 1 year
  13. The patient has received an drug or device within 30 days or 5 half-lives, whichever is greater, of enrollment
  14. Patient has, in the opinion of the Investigator, a condition that compromises the ability of the subject to give written or to comply with study procedures, including scheduled self-administration of oral CK-1827452
  15. The patient has had any prior treatment with CK-1827452
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Cohort 1: MR 50 mg BID

    Modified-release (MR) 50 mg dose of CK-1827452 twice a day (BID) for 10 days.

    Drug: CK-1827452

  • Experimental
    Cohort 2: IR 37.5 mg TID

    Immediate-release (IR) 37.5 mg dose of CK-1827452 three times a day (TID) for 10 days.

    Drug: CK-1827452

  • Experimental
    Cohort 3: MR 100 mg BID

    Modified-release (MR) 100 mg dose of CK-1827452 twice a day (BID) for 10 days

    Drug: CK-1827452

Interventions

  • 50 mg MR CK-1827452 BID for 10 days

  • 37.5 mg IR CK-1827452 TID for 10 days

  • 100 mg MR CK-1827452 BID for 10 days

06

What researchers measure

Primary outcomes

  1. C Max (Day 1, Dose 1)

    Maximum plasma concentration (C max) measured in nanograms per milliliter (ng/mL) post first dose and pre second dose on day 1. Doses are approximately 12 hours apart in cohort 1 and 3 and 8 hours apart in cohort 2.

    Time frame: 1 day

  2. T Max (Day 1, Dose 1)

    Time of observed maximum plasma concentration (T max) measured in hours (hr) post first dose and pre second dose on day 1. Doses are approximately 12 hours apart in cohort 1 and 3 and 8 hours apart in cohort 2.

    Time frame: 1 day

  3. AUC (Day 1, Dose 1)

    Area under the curve (AUC) measured in hours \* nanograms per milliliter (hr\*ng/mL) post first dose and pre second dose on day 1. Doses are approximately 12 hours apart in cohort 1 and 3 and 8 hours apart in cohort 2.

    Time frame: 1 day

  4. C Max (Day 10)

    Maximum plasma concentration (C max) measured in nanograms per milliliter (ng/mL) post dose on day 10. Only one dose was administered on day 10 (final dose of study).

    Time frame: 1 day

  5. T Max (Day 10)

    Time of observed maximum plasma concentration (T max) measured in hours (hr) post dose on day 10. Only one dose was administered on day 10 (final dose of study).

    Time frame: 1 day

  6. AUC (Day 10)

    Area under the curve (AUC) measured in hours \* nanograms per milliliter (hr\*ng/mL) post dose on day 10. Only one dose was administered on day 10 (final dose of study).

    Time frame: 1 day

Secondary outcomes

  1. Evaluate the Safety and Tolerability of Oral Formulations of CK-1827452 When Dosed to Steady-state in Patients With Stable Heart Failure.

    Time frame: 1 week

07

Results

Posted Dec 21, 2010

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: MR 50 mg BIDCohort 2: IR 37.5 mg TIDCohort 3: MR 100 mg BID
Started121112
Completed121012
Not completed010

Outcome measures

PrimaryC Max (Day 1, Dose 1)

Maximum plasma concentration (C max) measured in nanograms per milliliter (ng/mL) post first dose and pre second dose on day 1. Doses are approximately 12 hours apart in cohort 1 and 3 and 8 hours apart in cohort 2.

Time frame:
1 day
Reported as:
Mean · ng/mL
C Max (Day 1, Dose 1)
ng/mLCohort 1: MR 50 mg BIDCohort 2: IR 37.5 mg TIDCohort 3: MR 100 mg BID
C Max (Day 1, Dose 1)58 ± 27243 ± 148209 ± 164
SecondaryEvaluate the Safety and Tolerability of Oral Formulations of CK-1827452 When Dosed to Steady-state in Patients With Stable Heart Failure.
Time frame:
1 week

Results for this outcome have not been posted.

PrimaryT Max (Day 1, Dose 1)

Time of observed maximum plasma concentration (T max) measured in hours (hr) post first dose and pre second dose on day 1. Doses are approximately 12 hours apart in cohort 1 and 3 and 8 hours apart in cohort 2.

Time frame:
1 day
Reported as:
Mean · hr
T Max (Day 1, Dose 1)
hrCohort 1: MR 50 mg BIDCohort 2: IR 37.5 mg TIDCohort 3: MR 100 mg BID
T Max (Day 1, Dose 1)3.5 ± 2.93.7 ± 3.73.5 ± 3.9
PrimaryAUC (Day 1, Dose 1)

Area under the curve (AUC) measured in hours \* nanograms per milliliter (hr\*ng/mL) post first dose and pre second dose on day 1. Doses are approximately 12 hours apart in cohort 1 and 3 and 8 hours apart in cohort 2.

Time frame:
1 day
Reported as:
Mean · hr*ng/mL
AUC (Day 1, Dose 1)
hr*ng/mLCohort 1: MR 50 mg BIDCohort 2: IR 37.5 mg TIDCohort 3: MR 100 mg BID
AUC (Day 1, Dose 1)446 ± 2061003 ± 3871650 ± 1354
PrimaryC Max (Day 10)

Maximum plasma concentration (C max) measured in nanograms per milliliter (ng/mL) post dose on day 10. Only one dose was administered on day 10 (final dose of study).

Time frame:
1 day
Reported as:
Mean · ng/mL
C Max (Day 10)
ng/mLCohort 1: MR 50 mg BIDCohort 2: IR 37.5 mg TIDCohort 3: MR 100 mg BID
C Max (Day 10)205 ± 111420 ± 158704 ± 494
PrimaryT Max (Day 10)

Time of observed maximum plasma concentration (T max) measured in hours (hr) post dose on day 10. Only one dose was administered on day 10 (final dose of study).

Time frame:
1 day
Reported as:
Mean · hr
T Max (Day 10)
hrCohort 1: MR 50 mg BIDCohort 2: IR 37.5 mg TIDCohort 3: MR 100 mg BID
T Max (Day 10)1.8 ± 0.91.8 ± 1.12.7 ± 1.6
PrimaryAUC (Day 10)

Area under the curve (AUC) measured in hours \* nanograms per milliliter (hr\*ng/mL) post dose on day 10. Only one dose was administered on day 10 (final dose of study).

Time frame:
1 day
Reported as:
Mean · hr*ng/mL
AUC (Day 10)
hr*ng/mLCohort 1: MR 50 mg BIDCohort 2: IR 37.5 mg TIDCohort 3: MR 100 mg BID
AUC (Day 10)1886 ± 10022118 ± 6236457 ± 5147

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: MR 50 mg BID—0/12 (0%)0/12 (0%)
Cohort 2: IR 37.5 mg TID—1/11 (9.1%)0/11 (0%)
Cohort 3: MR 100 mg BID—0/12 (0%)2/12 (16.7%)
Most frequent serious events
Most frequent serious events
EventCohort 1: MR 50 mg BIDCohort 2: IR 37.5 mg TIDCohort 3: MR 100 mg BID
Sudden deathGeneral disorders0/121/110/12
Most frequent other events
Most frequent other events
EventCohort 1: MR 50 mg BIDCohort 2: IR 37.5 mg TIDCohort 3: MR 100 mg BID
Ventricular extrasystolesCardiac disorders0/120/111/12
Influenza like illnessGeneral disorders0/120/111/12

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1: MR 50 mg BIDCohort 2: IR 37.5 mg TIDCohort 3: MR 100 mg BIDTotal
<=18 years0000
Between 18 and 65 years78621
>=65 years53614
Age Continuous
Age Continuous(years)Cohort 1: MR 50 mg BIDCohort 2: IR 37.5 mg TIDCohort 3: MR 100 mg BIDTotal
Mean64.1 ± 7.7461.1 ± 7.9762.4 ± 11.5162.6 ± 9.08
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: MR 50 mg BIDCohort 2: IR 37.5 mg TIDCohort 3: MR 100 mg BIDTotal
Female43411
Male88824
Region of Enrollment
Region of Enrollment(participants)Cohort 1: MR 50 mg BIDCohort 2: IR 37.5 mg TIDCohort 3: MR 100 mg BIDTotal
Georgia12111235
08

Study locations

3 sites
  • Cardio-Reanimation Centre
    Tbilisi, Georgia
  • Diagnostic Services Clinic
    Tbilisi, Georgia
  • Tbilisi State Medical University Clinic #1
    Tbilisi, Georgia
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2010, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2009
First posted
Jul 17, 2009
Start
Apr 2009
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Dec 21, 2010
Last update
Feb 12, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00941681
Lead sponsor
Cytokinetics
Responsible party
Sponsor
First posted
Jul 17, 2009
Start date
Apr 2009
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Dec 21, 2010
Last update
Feb 12, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omecamtiv mecarbil

Start the discussion